The RAS-regulated RAF-MEK1/2-ERK1/2 signalling pathway is activated in a variety of cancers due to mutations in RAS (especially KRAS), BRAF and more rarely CRAF, MEK1 or MEK21–4. This evidence concerns the gene MAP2K1 and cancer.